Neuroleptics page


Neuroleptics (antipsychotics) In 1973, psychiatrist George Crane gained the attention of the medical community by disclosing that many, and perhaps most, long-term neuroleptic patients were developing a largely irreversible, untreatable neurological disorder, tardive dyskinesia. The disease, even its mild forms, is often disfiguring, with involuntary movements of the face, mouth […]

Read More

$6.7 million verdict in Risperdal TD case

  On May 26, 2000, a jury in the circuit court of Philadelphia awarded $6.7 million to a patient afflicted with tardive dyskinesia caused by the neuroleptic (“antipsychotic”) drug Risperdal (generic name, risperidone).  In Liss vs. Doeff, the jury found the psychiatrist negligent in his treatment of Mrs. Elizabeth Liss.  […]

Read More

$1.6 million TD verdict

When she was twenty-one years old in 1982, Sylvia became anxious and depressed over events in her life. Her internist at the time placed her on Triavil, a combination of the neuroleptic perphenazine (Trilafon) and the antidepressant amitriptyline (Elavil). Although most of her symptoms of anxiety cleared up over the […]

Read More

TD case settled after Breggin testimony

A tardive dyskinesia malpractice case was settled in trial following testimony by psychiatrist Peter R. Breggin, M.D. on behalf of the plaintiff in November 2001.  The settlement amount was not disclosed but was considered more than satisfactory by the plaintiff.  Dr. Breggin was the plaintiff’s only expert.  Dr. Breggin has […]

Read More

Spearheading a Transformation (1996)

Introduction to Psychosocial Approaches to Deeply Disturbed Persons (1996) Spearheading a Transformation Peter R. Breggin In recent years, pharmacology and psychiatric hospitalization have become the standard for most professionals when “treating schizophrenia.” Meanwhile, a body of research and practical experience has been evolving that supports innovative psychosocial interventions as less […]

Read More